BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 30, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

DNA in drug capsules

$85M series A fortifies Rampart push in DNA-based therapies

Oct. 24, 2023
By Randy Osborne
Emerging from stealth mode, Rampart Bioscience Inc. pulled down $85 million in series A money for work on DNA-based drugs – a round that was led by Forbion with participation from seed investor Orbimed and new backers RA Capital Management and Healthcap.
Read More

Financings for Oct. 24, 2023

Oct. 24, 2023
Biopharmas raising money in public or private financings, including: Cargo, Coeptis, Dermbiont, Ensysce, Invea, Lipella, Lygenesis, Orbimed, Ultragenyx.
Read More
Science and medicine icons with head made of computer code

Phasev raises $15M for machine learning tool that optimizes clinical trials

Oct. 24, 2023
By Shani Alexander
Phasev Inc. has raised $15 million in a funding round that will allow the company to further develop its machine learning (ML) technology that aims to revolutionize clinical trial design, execution and analysis. The funding round was led by Viola Ventures and Exor Ventures and included participation from Lionbird and a group of prominent angel investors.
Read More

Financings for Oct. 24, 2023

Oct. 24, 2023
Med-tech firms raising money in public or private financings, including: Orbimed.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Med-tech firms raising money in public or private financings, including: Aurora.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Biopharmas raising money in public or private financings, including: Aligos, Applied Molecular Transport, Cyclo, Harpoon.
Read More

Abivax gains US listing, pads coffers with $236M in Nasdaq IPO

Oct. 20, 2023
By Jennifer Boggs
Abivax SA’s debut on the U.S. market received a somewhat chilly reception Oct. 20, as the firm priced on the low end of its proposed range and ended the first day of trading in the red. But the company managed to pull in about $235.8 million in gross proceeds, the majority of which will support late-stage efforts for obefazimod, an oral candidate with a novel mechanism of action it hopes to advance in the lucrative inflammatory bowel disease space.
Read More

Financings for Oct. 20, 2023

Oct. 20, 2023
Biopharmas raising money in public or private financings, including: Arcutis, Adial, Talaris, Tourmaline.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Biopharmas raising money in public or private financings, including: Abivax, Ultragenyx.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Med-tech firms raising money in public or private financings, including: Evident Vascular, Oxford Nanopore, Vitatek.
Read More
Previous 1 2 … 238 239 240 241 242 243 244 245 246 … 668 669 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing